Results from the DS8201-A-U105 study showed that nivolumab added to trastuzumab deruxtecan has some benefit for patients with HER2-positive breast cancer.
Tony Berberabe, MPH
Tony Berberabe, MPH, is the Editor for Targeted Therapies in Oncology. Berberabe received his Bachelor of Arts in Biology from Rutgers University and his Master of Public Health from the University of Medicine and Dentistry in New Jersey.
Articles by Tony Berberabe, MPH
In the context of oncology, the use of artificial intelligence/machine learning has enabled the growth of precision medicine, helping clinicians increase efficiency and accuracy, according to Alexander S.Baras, MD, PhD.
According to study investigators, "the number of invited women panelists increased during the study period with a subsequent decrease in proportion of manels, there are topics/specialties where female representation remains stagnant."
Results from the KEYNOTE-826 trial showed that chemotherapy plus pembrolizumab with or without bevacizumab improved overall survival and progrssion-free survival in patients with metastatic cervical cancer based on subgroups including histology and prior treatment type.
Data showing the safety and efficacy of selpercatinib for patients with solid tumors continues to impress clinicians at the 2022 ASCO Annual Meeting.
An exploratory analysis of the phase 3 Study 309/KEYNOTE-775 trial evaluating the efficacy of next line of therapy showed clinically meaningful improvements in second progression-free survival and duration of the next line of therapy in patients with previously treated advanced endometrial cancer who received lenvatinib and pembrolizumab vs physician’s choice of chemotherapy.
In the EPCORE NHL-2 trial , epcoritamab therapy was manageable and achieved high rates of response in patients with high-risk diffuse large B-cell lymphoma.
At the upcoming 23rd Annual International Lung Cancer Congress®, Solange Peters, MD, PhD will be giving two presentation around relevant biomarkers in perioperative immunotherapy and the role of treatment agent sequencing in ALK-rearranged non–small cell lung cancer.
Thomas Flaig, MD, addressed new and emerging systemic therapies for bladder cancer during the National Comprehensive Cancer Network 2022 Annual Conference.
Targeted agents, such as Bruton tyrosine kinase inhibitors, PI3K inhibitors, B-cell lymphoma 2 inhibitors, and venetoclax, have delivered improvements in quality of life, progression-free survival, and overall survival for relapsed/refractory chronic lymphocytic leukemia.
Health-related quality-of-life outcomes were maintained among patients with low grade non-muscle invasive bladder cancer who were treated with UGN-102, a chemoablative reverse thermal gel as a primary approach in the single-arm phase 2b Optima II trial.
Interim results from a biomarker-informed preoperative study of infigratinib demonstrated substantial activity and tolerability in patients with localized upper tract urothelial carcinoma, according to findings of a phase 1b trial.
Continued benefit of axicabtagene ciloleucel in patients with relapse/refractory indolent non-Hodgkin lymphoma was observed in the phase 2 ZUMA-5 clinical trial.
RP-3500 dosed at 160-mg dose on a 3 days on/4 days off continuous cycle appears to be the most tolerable for patients with selected ATR-inhibitor-sensitizing DNA damage response alterations, according to the TRESR study.
Response were observed with the combination of sotigalimab and pembrolizumab in patients with metastatic melanoma treated in a phase 1/2 study.
Pertuzumab combined with trastuzumab, and docetaxel revealed comparable survival outcomes with previous studies of patients with metastatic breast cancer, including the CLEOPATRA trial.
Pan-immune-inflammation value made be predictive of survival benefit in patients with ALK-positive non–small cell lung cancer.
A significant proportion of patients who complete 2 years of immune checkpoint inhibitor treatment experience long-term progression-free survival.
Thromboembolic events and risk of progression continue to affect patients with polycythemia vera, but 2 recent advances may affect the natural course of the disease.
Using next-generation sequencing to help inform treatment options is growing in frequency, but the results can be difficult to interpret and implement in clinical practice.
Time to event end points and response rates were similar regardless of which first-line immunotherapy was administered, according to an analysis conducted by the International Metastatic Renal Cell Carcinoma Database Consortium
Patients with urothelial cancer whose tumors overexpress c-Met may benefit from this unique combination.
For localized colorectal cancer, the use of circulating tumor tDNA for both quantitative and qualitative detection can inform the risk of recurrence and metastatic dissemination.
Neoadjuvant treatment with pembrolizumab, paclitaxel, and cisplatin achieved encouraging tumor responses in patients with locally advanced resectable esophageal squamous cell carcinoma.
Debu Tripathy, MD, said the 39th Annual Miami Breast Cancer Conference is always a well-rounded meeting.
Investigation of intravesical checkpoint-targeted therapy may warrant further investigation in patients with BCG-unresponsive bladder cancer.
Current findings validate and support the clinical utility of enzalutamide regardless of metastatic burden or type of oligometastatic disease, according to the investigators.
Innovative approaches in multiple myeloma that focus on cellular therapies offer hope to patients with multiple myeloma.
The most effective treatment strategy—adjuvant, neoadjuvant, or some combination of adjuvant plus neoadjuvant regimens— remains unclear. Ongoing trials are dedicated to defining the best sequence of treatment.
The improvement in detection and treatment associated with PSMA cannot be overstated, with many investigators describing the advancement as a global practice changer.